Pharmaceutical services firm Hvivo has announced plans to open a larger facility in response to the company’s growing order book. The new facility will be located in Canary Wharf, with the expansion largely funded by Hvivo client looking to accelerate their studies.

The specialised facility will contain around fifty quarantine bedrooms along with advanced laboratories, an outpatient unit and corporate offices across two floors. It will support the company in conducting more challenge trials concurrently. The new laboratories will also increase sample throughput, expanding Hvivo’s capacity to work with a broader range of pathogens.

While the company’s existing Whitechapel and Queen Mary Bioenterprises Centre clinics will shut next year, the centres will remain open until the new facility is completed. The first phase of the facility is expected to be completed in the first three months of next year and be fully operational by the second quarter of the year.

“The new facility will feature increased capacity and offer the potential for up to 70 quarantine beds, which will enable us to increase the capacity for the company to generate revenues,” said chief executive Yamin Khan adding that it would allow the company to conduct a greater number of trials concurrently across various challenge models enabling it to maintain a higher level of capacity throughout the year.